Biomarin

BioMarin's Record Q1 Driven by Recently Approved Achondroplasia Therapy
BioSpace
Wed, 04/27/22 - 10:44 pm
Biomarin
earnings
Another phenylketonuria hold, courtesy of Homology
EP Vantage
Tue, 02/22/22 - 10:43 am
Homology Medicines
HMI-102
Biomarin
BMN 307
FDA
clinical trials
clinical hold
PKU
BioMarin says gene therapy hold will endure as FDA questions cancer risk
BioPharma Dive
Sun, 02/20/22 - 11:54 am
Biomarin
FDA
gene therapy
clinical trials
FDA grounds BioMarin gene therapy trial for months with demand for tumor risk data
Fierce Biotech
Fri, 02/18/22 - 10:32 am
Biomarin
FDA
clinical trials
clinical hold
BMN 307
PKU
gene therapy
BioMarin's hemophilia A gene therapy hits goal in phase 3, teeing up FDA filing despite durability doubts
Fierce Biotech
Mon, 01/10/22 - 11:32 am
Biomarin
hemophilia A
gene therapy
valrox
clinical trials
FDA approves first drug for genetic cause of dwarfism
Stat
Fri, 11/19/21 - 11:06 am
Biomarin
FDA
dwarfism
achondroplasia
Voxzogo
BioMarin's new launch Voxzogo could surprise investors and become a blockbuster brand: analyst
Fierce Pharma
Mon, 11/15/21 - 12:24 pm
Biomarin
FDA
Voxzogo
dwarfism
Go or go go? J&J’s cell therapy heads to the FDA
EP Vantage
Fri, 10/29/21 - 10:33 am
JNJ
cilta-cel
Multiple Myeloma
FDA
Biomarin
Merck
molnupiravir
Looking to win back investor confidence, BioMarin preps for its ‘largest launch’
Endpoints
Thu, 10/28/21 - 10:47 am
Biomarin
Voxzogo
drug launches
achrondoplasia
5 FDA approval decisions to watch in the fourth quarter
BioPharma Dive
Sun, 10/3/21 - 08:32 pm
FDA
vaccines
COVID-19
Pfizer
BioNTech
JNJ
cilta cel
Biomarin
vosoritide
Intra-Cellular Therapies
lumateperone
Moderna Therapeutics
FDA halts tests of BioMarin drug amid heightened focus on gene therapy safety
BioPharma Dive
Tue, 09/7/21 - 10:51 am
FDA
Biomarin
gene therapy
phenylketonuria
clinical trials
BioMarin stands tall with first approved drug for rare disease that causes dwarfism
MedCity News
Sat, 08/28/21 - 08:57 pm
Biomarin
Europe
achondroplasia
dwarfism
Incyte
MorphoSys
Get Ready for a Potential Double in This Biopharmaceutical Stock in the Next 6 to 12 Months
Motley Fool
Fri, 08/20/21 - 10:57 am
Biomarin
Voxzogo
BioMarin gears up for two 'transformational' launches, Voxzogo and Roctavian: CEO
Fierce Pharma
Mon, 08/2/21 - 09:36 pm
Biomarin
Pharma CEOs
J.J. Bienaimé
BioMarin's gene therapy lead jumps ship to rival biotech Vedere Bio II
Fierce Biotech
Tue, 06/22/21 - 11:11 am
Vedere Bio II
gene therapy
Biomarin
BioMarin (BMRN) Hemophilia Gene Therapy Gets FDA's RMAT Tag
Yahoo/Zacks.com
Tue, 03/9/21 - 10:37 am
Biomarin
gene therapy
hemophilia A
valoctocogene roxaparvovec
FDA
RMAT
Gene therapy for hemophilia: So close, yet so far away
BioPharma Dive
Thu, 01/28/21 - 11:18 pm
hemophilia
hemophilia A
hemophilia B
gene therapy
Biomarin
uniQure
10 key clinical trials to watch in the first half of 2021
BioPharma Dive
Sun, 01/17/21 - 05:01 pm
clinical trials
Novavax
AstraZeneca
JNJ
vaccines
COVID-19
Biomarin
Amgen
Merck
Pfizer
Roche
SAGE Therapeutics
Biogen
Vertex Pharmaceuticals
BioMarin tries to get hemophilia gene therapy back on track with positive data
BioPharma Dive
Mon, 01/11/21 - 10:40 am
Biomarin
hemophilia A
gene therapy
clinical trials
Roctavian
10 Biopharma Stories to Look Forward to in 2021
BioSpace
Sun, 01/3/21 - 04:39 pm
pandemic
COVID-19
vaccines
Joe Biden
drug pricing
M&A
venture capital
JNJ
Biomarin
Bluebird Bio
TG Therapeutics
Biogen
AstraZeneca

Pages